



September 8, 2025

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides Enters into a Strategic Product Development Partnership with Kenox  
to Expand Nasal Spray Portfolio for the US Market”**

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
**Company Secretary**  
**ICSI Membership No. A30515**

Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

**Corp. Off:** Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India

**Tel:** +91-80-6784 0000 **Fax:** +91 80 6784 0700

**Regd Off:** 'Cyber One', Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India

**Tel:** +91-22-2789 2924/ 3199

corpcomm@strides.com; www.strides.com

## Strides Enters into a Strategic Product Development Partnership with Kenox to Expand Nasal Spray Portfolio for the US Market

- *Partnership strengthens Strides' pipeline of nasal spray products across diverse therapeutic areas*
- *Kenox to provide formulation and development expertise in Orally Inhaled and Nasal Drug Products (OINDPs)*
- *Collaboration aims to accelerate affordable, high-quality medicines for patients in the US*

**Bangalore, India, September 8, 2025:** Strides Pharma Science Ltd (BSE: 532531, NSE: STAR), today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. ("Kenox"), a fast-growing contract development and manufacturing company specializing in Orally Inhaled and Nasal Drug Products (OINDPs).

Under the terms of the agreement, Strides will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications. Specific product details remain confidential at this stage.

*"We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain. With continued investments in the capabilities and capacities at our US facility, these products are a natural fit within our strategy to expand into our nasal spray technology domain. Kenox's formulation and development strengths perfectly complement our manufacturing and go-to-market strengths allowing us to accelerate our range of nasal spray offerings in the US market."* **said Aditya Kumar, Executive Director Business Development, Strides Pharma Science Limited.**

**Dr. Sitaram Velaga, Founder, President and CEO of Kenox Pharmaceuticals Inc.,** added:

*"Our strategic partnership with Strides is a significant milestone for Kenox. This collaboration validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price."*

The partnership will advance a pipeline of nasal spray products for the US market, combining Strides' commercial strengths with Kenox's OINDP expertise to deliver affordable, high-quality therapies to patients.

### About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com).

## About Kenox

Established in 2018 and based in greater Princeton, NJ, Kenox specializes in pharmaceutical aerosol product development, including soft mist inhalers (SMIs), dry powder inhalers (DPIs), nebulizers, and nasal sprays. As a contract development organization, Kenox offers a wealth of expertise in formulation design, compounding, fill and finish, and testing in compliance with compendial monographs.

### For further information, please contact:

<b><u>Institutional Investors</u></b> <b>Vikesh Kumar</b> Group CFO Email: <a href="mailto:investor-relations@strides.com">investor-relations@strides.com</a> <b>Saurabh Ambaselkar</b> Investor Relations - +91 99609 31220 Email: <a href="mailto:saurabh.ambaselkar@strides.com">saurabh.ambaselkar@strides.com</a>  <b><u>Strides Pharma Science Limited</u></b> CIN: L24230MH1990PLC057062 Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076	<b><u>Corporate Communication</u></b> <b>Pallavi Panchmatia:</b> +91 80 6784 0193 Email: <a href="mailto:pallavi.panchmatia@strides.com">pallavi.panchmatia@strides.com</a> <b>Janhavi Bellare:</b> +91 93228 54508 <a href="mailto:Janhavi.bellare@adfactorspr.com">Janhavi.bellare@adfactorspr.com</a> <b>Talal Syed:</b> +91 99876 19679 <a href="mailto:syed.talal@adfactorspr.com">syed.talal@adfactorspr.com</a>
---	--

## Kenox Media/Investor Contact

Sitaram Velaga

Email: [info@kenoxpharma.us](mailto:info@kenoxpharma.us)